ℹ️
🇨🇿
Hledání
Hledat osoby relevantní k dotazu "IMiD"
IMiD
Osoba
Předměty
Osoby
Publikace
Studium
Mgr. Jan Kubeš
Akademický pracovník na Farmaceutická fakulta v Hradci Králové
10 publikací
Publikace
publication
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
2020 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1
2023 |
Farmaceutická fakulta v Hradci Králové
publication
Hydrophobicity-enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells
2023 |
Farmaceutická fakulta v Hradci Králové
publication
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up
2022 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions
2021 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo
2021 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation
2021 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
2021 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline
2019 |
Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
publication
2,6-Dihydroxybenzaldehyde analogues of the iron chelator salicylaldehyde isonicotinoyl hydrazone: Increased hydrolytic stability and cytoprotective activity against oxidative stress
2018 |
Farmaceutická fakulta v Hradci Králové
Loading network view...